Increase access to these therapies nationwide, with particular attention to the access centers in the South

Generation of effective constructs for the treatment of rare genetic diseases

Standardized tests for safety studies of products before their clinical use

Production of pharmaceutical products in facilities approved by the competent Italian Agency (AIFA)